Clinical course of patients with relapsed multiple myeloma.
暂无分享,去创建一个
T. Therneau | R. Fonseca | A. Dispenzieri | R. Kyle | D. Larson | Shaji K. Kumar | S. Rajkumar | M. Gertz | P. Greipp | J. Lust | T. Witzig | M. Lacy | R. Kyle
[1] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[2] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[3] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[4] T. Ishibashi,et al. Ten-Year Survivor with Multiple Myeloma in First Complete Remission following Treatment with Conventional Chemotherapy , 2001, Acta Haematologica.
[5] D. Vesole,et al. Relapsed multiple myeloma , 2001, Current treatment options in oncology.
[6] S. Rajkumar. Thalidomide in multiple myeloma. , 2000, Oncology.
[7] P. Grambsch,et al. Modeling Survival Data: Extending the Cox Model , 2000 .
[8] S. Rajkumar,et al. Prognostic factors in multiple myeloma. , 1999, Hematology/oncology clinics of North America.
[9] F. Gieseler,et al. Cellular resistance mechanisms with impact on the therapy of multiple myeloma , 1998, Leukemia.
[10] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[11] B. Barlogie,et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. , 1995, Bone marrow transplantation.
[12] A. Cortelezzi,et al. Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study , 1995, British journal of haematology.
[13] A. Paccagnella,et al. Second and third responses to the same induction regimen in relapsing patients with multiple myeloma , 1991, Cancer.
[14] E. Montserrat,et al. A new prognostic system for multiple myeloma based on easily available parameters , 1989, British journal of haematology.
[15] B. Simonsson,et al. Prognostic value of serum lactic dehydrogenase (S‐LDH) in multiple myeloma , 1987, European journal of clinical investigation.
[16] B. Barlogie,et al. Therapy of primary resistant and relapsed multiple myeloma. , 1986, Onkologie.
[17] R. Bataille,et al. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. , 1983, British journal of haematology.
[18] B. Barlogie,et al. The growth fraction of human myeloma cells. , 1981, Blood.
[19] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[20] E. Gehan,et al. Unmaintained remissions in multiple myeloma. , 1978, Blood.
[21] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[22] R. Fonseca,et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. , 2003, Mayo Clinic proceedings.
[23] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.
[24] B. Barlogie,et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.
[25] Mike Clarke,et al. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] C. Tinelli,et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. , 1998, British Journal of Cancer.
[27] Lust,et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.
[28] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[29] R. Kyle. Multiple myeloma: review of 869 cases. , 1975, Mayo Clinic proceedings.